Search results with tag "1 indications and usage"
Prescribing Information | SUBLOCADE® (buprenorphine ...
www.sublocade.com14.1 Study 13-0002, NCT02044094 . 14.2 Study 13-0001, NCT02357901 . 16 HOW SUPPLIED/STORAGE AND HANDLING . 17 PATIENT COUNSELING INFORMATION . 1 INDICATIONS AND USAGE . 2 DOSAGE AND ADMINISTRATION . 2.1 Drug Addiction Treatment Act . 2.2 Important Dosing and Administration Information
HIGHLIGHTS OF PRESCRIBING INFORMATION …
docs.boehringer-ingelheim.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 11/2021 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Not for Acute Use 5.2 …
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.gilead.com1 INDICATIONS AND USAGE 8.2 2 DOSAGE AND ADMINISTRATION 2.1 Testing Before Initiating and During Treatment with VEKLURY 2.2 Recommended Dosage in Adults and Pediatric Patients 12 Years of Age and Older and Weighing at Least 40 kg 2.3 Renal Impairment 2.4 Dose Preparation and Administration 2.5 Storage of Prepared Dosages ...
HIGHLIGHTS OF PRESCRIBING INFORMATION LEQVIO …
www.novartis.usSee 17 for PATIENT COUNSELING INFORMATION. Revised: 12/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Important Administration Instructions 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 6 ADVERSE REACTIONS …
HIGHLIGHTS OF PRESCRIBING INFORMATION heart failure …
www.novo-pi.com1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions 2.2 Route of Administration 3 . 2 oronmnf ti a I Dgeaos 2.4 Dosage Adjustment Due to Drug Interactions 2.5 Instructions for Mixing with Other Insulins 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION - GSKpro
gskpro.com*Sections or subsections omitted from the full prescribing information are not listed. _____ FULL PRESCRIBING INF ORMATION . 1 INDICATIONS AND USAGE . 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease . TRELEGY ELLIPTA 100/62.5/25 mcg is indicated for the maintenance treatment of patients with chronic obstructive pulmonary ...
HIGHLIGHTS OF PRESCRIBING INFORMATION • Administer …
www.biogencdn.comFULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or
1 INDICATIONS AND USAGE - Food and Drug …
www.accessdata.fda.gov1 INDICATIONS AND USAGE . Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. 2 DOSAGE AND ADMINISTRATION . 2.1 Recommended Dosage
1 INDICATIONS AND USAGE 2 DOSAGE AND …
www.radicava.com1 INDICATIONS AND USAGE RADICAVA is indicated for the treatment of amyotrophic lateral sclerosis (ALS). 2 DOSAGE AND ADMINISTRATION 2.1 Dosage Information The recommended dosage of RADICAVA is an intravenous infusion of 60 mg administered over a 60-minute period according to the following schedule: ...